Open AccessAn Overview of Quadrivalent Human Papillomavirus Vaccine Safety
Author(s) -
Michelle Vichnin,
Paolo Bonanni,
Nicola P. Klein,
Suzanne M. Garland,
Stan L. Block,
Susanne K. Kjær,
Heather L. Sings,
Gonzalo Pérez,
Richard M. Haupt,
Alfred J. Saah,
Fabio Lievano,
Christine Velicer,
Rosybel Drury,
Barbara J. Kuter
Publication year - 2015
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000000793
Subject(s) - medicine , genital warts , vaccination , population , incidence (geometry) , cervical cancer , clinical trial , adverse effect , public health , pediatrics , immunology , environmental health , cancer , pathology , physics , optics
A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine (GARDASIL/SILGARD®) has been licensed in many countries around the world for the prevention of cervical, vulvar, vaginal, and anal cancers and precancers, as well as external genital warts causally related to HPV types 6/11/16/18. Across 7 phase 3 clinical trials involving more than 29,000 males and females ages 9-45 years, vaccination was generally well tolerated. Because of its expected public health benefit in reducing cervical cancer and other HPV-related diseases, the vaccine has been implemented in the national vaccination programs of several countries, with over 178 million doses distributed worldwide.